Impact BioMedical, Inc. (IBO) is a publicly traded Healthcare sector company. As of May 21, 2026, IBO trades at $0.53 with a market cap of $58.04M and a P/E ratio of -1.52. IBO moved +4.03% today. Year to date, IBO is +3.30%; over the trailing twelve months it is -3.03%. Its 52-week range spans $0.36 to $6.17. Rallies surfaces IBO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in IBO news today?
Impact Biomedical Gains 86% After-Hours on Merger Amendment Extending Deal to July 2026: Impact Biomedical’s shares jumped 86.28% after-hours on an amendment extending its merger deadline to July 1, 2026. Revised terms grant Dr Ashleys Bio Labs 94.20% of shares at closing and allot up to 128,000 shares to DSS, Inc. for funding and hold harmless obligations.
Macko Todd D sold 43.40K (~$24.37K) on Mar 27, 2026.
Macko Todd D sold 1.60K (~$961.28) on Mar 25, 2026.
Grady Jason sold 50.00K (~$32.51K) on Mar 23, 2026.
IBO Analyst Consensus
IBO analyst coverage data. Average price target: $0.00.
Common questions about IBO
What changed in IBO news today?
Impact Biomedical Gains 86% After-Hours on Merger Amendment Extending Deal to July 2026: Impact Biomedical’s shares jumped 86.28% after-hours on an amendment extending its merger deadline to July 1, 2026. Revised terms grant Dr Ashleys Bio Labs 94.20% of shares at closing and allot up to 128,000 shares to DSS, Inc. for funding and hold harmless obligations.
Does Rallies summarize IBO news?
Yes. Rallies summarizes IBO news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is IBO research on Rallies investment advice?
No. Rallies provides research, data, and educational context for IBO. It does not provide personalized investment advice.
